Ticker brief
NKTR NEKTAR THERAPEUTICS
Consumer, Non-cyclical · Biotechnology
last close
$72.52
1 day
-2.7%
14 days
-0.7%
mkt cap
$2.4B
signals 14d
13
authors 14d
8
crowd 14d
+0.5σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 63% cheap · 13 pctile own 1y | IV/HV 1.24× |
| Skew — 25Δ RR 30d | +0.016 43 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +1.65 normal | 5-session Δ -1.23 (as of 2026-07-16) |
| OI alarm | quiet | last alarm 2026-04-21 (z=4.2) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-16 → 2026-08-27 · now +0.40 (−1 bearish … +1 bullish)
Who spoke8
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -3.01 | 4 | +0.49 |
| @AponiaAnalytics | B | +4.91 | 2 | -0.05 |
| @LogicalThesis | A | +2.21 | 2 | +0.40 |
| @OpenOutcrier | C | · | 1 | +0.40 |
| @PortfolioArmor | C | -1.71 | 1 | +0.00 |
| @BiopharmIQ | B | · | 1 | +0.20 |
| @PersimmonTI | A | -0.57 | 1 | +0.35 |
| @BioStocks | C | -3.02 | 1 | +0.55 |
Recent signals13of 13 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-27 | @semodough | +0.40 | B. Riley sets a $150 target while highlighting late-September and early-Q4 catalysts. | -2.7% | tweet ↗ |
| 2026-08-26 | @semodough | +0.40 | B. Riley rates NKTR Buy with a $150 target and cites favorable litigation rulings and potential damages. | -1.7% | tweet ↗ |
| 2026-08-25 | @BioStocks | +0.55 | Lancet publication reports NKTR's Phase 2b study met all primary and key secondary endpoints. | -3.3% | tweet ↗ |
| 2026-08-23 | @PersimmonTI | +0.35 | Sees sustained scientific momentum for regulatory-T-cell therapies across indications. | -2.0% | tweet ↗ |
| 2026-08-22 | @BiopharmIQ | +0.20 | Q2 13F data quantify how many of 36 biopharma hedge funds held each named stock. | -2.0% | tweet ↗ |
| 2026-08-22 | @LogicalThesis | +0.00 | Cites historical pre-readout prices for ABVX and NKTR without a current stance. | -2.0% | tweet ↗ |
| 2026-08-21 | @PortfolioArmor | +0.00 | Links a recap of trades exited during the week without providing results in the tweet. | -2.0% | tweet ↗ |
| 2026-08-21 | @LogicalThesis | +0.80 | Recaps another trader's successful 10-bagger pitches and the author's borrowed conviction. | -2.0% | tweet ↗ |
| 2026-08-21 | @OpenOutcrier | +0.40 | Lists analyst upgrades; output is capped at the first six tickers. | -2.0% | tweet ↗ |
| 2026-08-18 | @AponiaAnalytics | -0.05 | Reports a planned sale of 186 vested shares, while noting it is mainly tax-related. | -1.5% | tweet ↗ |
| 2026-08-18 | @AponiaAnalytics | -0.05 | Reports a director's planned sale of 418 vested shares, including shares for taxes. | -1.5% | tweet ↗ |
| 2026-08-17 | @semodough | +0.40 | B. Riley rates NKTR Buy with a $150 target, citing an FDA path and multiple upcoming catalysts. | -0.2% | tweet ↗ |
| 2026-08-16 | @semodough | +0.75 | Cowen sees a large underpenetrated AD market and projects Rezpeg can generate $6B-plus across indications. | -0.7% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.